News and price dashboard

The tape behind today's feed

Almost everything in this section was filed into a down day for US equities. The quote panels on the Investing.com pages read through the full-text items show the Nasdaq at 25,437, down 2.86%, the S&P 500 at 7,579.86, down 1.82%, the Dow down 1.09%, and the VIX up 13.02% to 19.44. The damage was concentrated in semis and hardware: Intel down 28.58% on 444.7 million shares, Sandisk down 13.42%, Datadog down 11.49%, Qualcomm down 11.13%, Astera Labs down 10.93%, AMD down 10.88%, Dell down 10.77%, Nvidia down 4.22%. The site's own most-read list points at the causes it is reporting: Intel's weak outlook dragging global chip names, the Nasdaq heading for its worst month since March 2025 on the AI trade, and a record hack at Binance that halted withdrawals and knocked digital assets and crypto stocks. In London the FTSE 100 finished essentially flat at 10,729.78, held up by AstraZeneca up 6.96% and BT up 6.71% against NatWest down 8.75% and Lloyds down 5.23%.

Iradimed at a 52-week low

Of the full-text items, Iradimed had the biggest single-name move, the stock marked at minus 10.57% as it hit a 52-week low of $76.39. The article ties this to the Q3 print: record revenue of $24.2 million against a $23.47 million forecast, up 14% year on year and 18% on the prior quarter, with non-GAAP EPS of $0.55 in line with estimates. The company trimmed the upper end of its full-year outlook alongside a decision to keep production growth controlled for quality reasons, which is the stated reason given for the sentiment shift. Market cap is $983 million, P/E 43, and the one-year total return is still near 14%.

Harley-Davidson and MarineMax at 52-week highs

Two 52-week highs with real content behind them. Harley-Davidson touched $31.13, up roughly 52% year to date, after a Q3 that actually missed on both lines, EPS of $0.40 against $0.47 expected and revenue of $964 million against $1.07 billion. The company lifted its outlook anyway, citing stronger retail demand, better margins and improved dealer health, and BofA Securities raised its target to $35 from $32 with a Buy rating, noting the result beat its own $0.21 EPS forecast. MarineMax hit $52.66, with a one-year total return of 121.8%, and the piece attributes the context to a reported $1.5 billion takeover including debt by Blackstone-owned Safe Harbor Marinas. Worth noting the same article carries the opposite signal on the underlying industry: Truist reported from the International BoatBuilders' Exhibition that the NMMA still rates major marine indicators as "caution" and "trouble" and forecasts a 3% to 5% drop in new powerboat retail sales in 2026, a sixth straight annual decline.

Two preferred shares at new lows

Both are AI-written Investing.com pieces with no company-specific cause given. SLM's Floating Rate Non-Cumulative Preferred Series B hit $69.15, a 52-week low, on a P/E of 6.24 and an 8.32% dividend yield, down 6.29% over a year but up 4.39% year to date; the article attributes the slide only to broader market trends. Bank OZK's 4.625% perpetual preferred Series A hit $14.55, down 14.55% over the past year, yielding 7.73%, with InvestingPro's fair value at $16.88. Again no specific driver, just "ongoing challenges and market conditions affecting the financial sector."

Revvity dividend and Red River earnings

Revvity's board declared a regular quarterly dividend of $0.07 a share, payable 12 February 2027 to holders of record on 22 January 2027. The company did 2025 revenue of $2.9 billion with about 11,000 employees; the stock was marked down 5.30% on the day. Red River Bancshares reported Q3 EPS of $1.90, seven cents above the $1.83 estimate, on revenue of $34.8 million versus $34.27 million consensus. The stock closed at $102.10, flat over three months but up 57% over twelve, and had one negative EPS revision and no positive ones in the prior 90 days.

The 8-K stubs are empty

Seven of the twenty full reads were Form 8-K notices with no body text at all, just the filing line and the ticker: NCL Corporation, Precision Optics, Lattice Semiconductor, Pioneer Bancorp, NeoVolta, Clear Secure and Cable One. There is nothing to read into them beyond the fact of a filing. The same applies to the long tail of headline-only 8-K and Form 4 entries further down, which make up a large share of the 200 items here.

Analyst notes, headline only

A cluster of rating changes, which I have only as headlines. Raymond James raised its Regeneron target to $1,020 on a strong quarter. Evercore ISI cut Reddit on user growth concerns, with a second headline saying monetisation may not offset traffic weakness. Freedom Broker was busy in both directions: upgrades on Mondelez (volume growth) and Garrett Motion (profitability), a downgrade on RPC (cash flow) and a target cut on Digital Realty (higher WACC).

Dividends, capital raising and compliance notices

Dividend declarations in the headline-only list: Entergy raising its quarterly to $0.68, Carlisle at $1.25, Leidos raising to $0.45, ArcBest at $0.12, Ralliant at $0.05. On the balance sheet side, Procter & Gamble closed a $4 billion multi-maturity notes offering, Citibank is redeeming $2.5 billion of notes due 2026, Norwegian Cruise Line secured $5 billion of credit facilities for new ships, and Walker & Dunlop amended its credit agreement to increase revolving commitments. Separately there is a run of exchange compliance problems, all headline only: 3e Network and SVRN facing Nasdaq delisting, Parabolic Technologies receiving a delisting notice, Origin Agritech with a bid price deficiency notice, and Accendra Health with an NYSE non-compliance notice.

Macro and odds and ends

Headline-only items worth knowing exist: Trump said he is looking at the Binance hack and whether North Korea was behind it; Tether nearly doubled its reserve buffer to $8 billion with Q3 profit holding steady; employers at the Los Angeles and Long Beach seaports and the maritime watchmen union extended talks through 5 November; cocoa stayed weak on rising ICE inventories and possible Brazilian sales, and coffee closed sharply lower on the week. The remainder of the section is TradingView chart posts, Nasdaq moving-average and oversold screener items, and insider Form 4 filings, none of which carry reportable content.

The backdrop behind most of today's single-stock moves

Nearly every full-text piece in this feed is an Investing.com "why is X moving" note, and they all lean on the same tape: the Nasdaq down roughly 2.3%, the S&P 500 off about 1.1%, and the VIX up around 10%, with heavy losses in Alphabet and Intel driving a broad risk-off tone and renewed questions about returns on AI infrastructure spending. The articles also reference a Fed that held rates steady at its October meeting, Q3 US GDP at a 3.4% annualised rate against a 3.2% consensus, and a hotter-than-expected PCE print. Headline-only items in the same feed point to gold falling 2% to about $3,939 an ounce, its lowest since November 2025, silver down 5.3% near $49.63, Brent near $117 after a tanker fire in the Strait of Hormuz, and a Binance hack that halted withdrawals and hit crypto-linked names. Read that as the shared driver under most of what follows.

Alphatec down about a third on biologics shortfall

The sharpest move covered in full was Alphatec Holdings, down 32.3% pre-open to $7.70. Q3 adjusted EPS came in at $0.09 against $0.10 expected and revenue at $221.17m versus $225.44m, with CEO Pat Miles attributing the miss directly to lower biologics attachment reducing revenue per surgical case. Full-year 2026 revenue guidance was cut to roughly $862m from about $882m, with biologics revenue now seen flat year on year. Needham cut its target to $12 from $14, TD Cowen to $10 from $13, and Stifel to $11 from $13, all three keeping constructive ratings and citing surgical case volume growth near 20% and expanding EBITDA margins as offsets. The stock's 52-week range is $6.82 to $23.29.

Coursera and Kioxia, guidance over results

Coursera fell 8.6% pre-open to $4.26 despite beating on both lines, with adjusted EPS of $0.21 on revenue of $376.7m. The problem was the outlook: Q4 revenue guidance of $358m to $366m against roughly $373m consensus, plus early 2027 commentary signalling possible revenue declines and EBITDA headwinds as it integrates the $2.5bn Udemy acquisition. JPMorgan went to Neutral with a $5 target, KeyBanc to Sector Weight, Needham kept Buy but cut its target to $6 from $10 citing soft web traffic and consumer weakness reviving AI-disruption fears, and Telsey cut to $7 from $10. Kioxia tells a similar story in a different sector, down 7.1% to ¥13,470 after guiding fiscal Q3 operating profit to ¥2.0 trillion against ¥2.35 trillion expected, even with a Q2 beat and a first-ever ¥90 dividend. The company flagged NAND average selling price growth slowing sharply, and the piece adds that Kioxia carries the largest leveraged long overhang on the Tokyo exchange and that China's YMTC passed it in NAND shipment rankings in Q2 2026. UBS trimmed its target ahead of the print; Goldman Sachs kept Buy. The Nikkei fell 2.12% on the day, led by chip names.

MasTec, FTAI and First Busey

MasTec dropped 5.2% pre-open to $168.5 on adjusted EPS of $2.96, a penny short, despite record quarterly revenue of $5.2bn versus $4.94bn expected and up 30% year on year. The guidance did the damage: full-year adjusted EPS midpoint of $9.11 against $9.27 consensus. Communications revenue shrank 12% to $807m as customers deferred spending, while the 18-month backlog hit a record $24.5bn, up 46%, with Power Delivery backlog up 74%. CFO Paul DiMarco pointed to over $1bn of 2026 operating cash flow. Citigroup and Stifel Nicolaus had already trimmed targets ahead of the print. FTAI Aviation slid 2.8% pre-open, giving back the prior session's surge after Q3 EPS of $1.43 missed the $1.50 consensus and revenue of $977.66m fell short of $998.12m, offsetting record adjusted EBITDA of $348.3m, up 17% year on year, and a doubled buyback authorisation to $1.0bn including a $500m accelerated repurchase with RBC. First Busey slipped 0.8% to $29.25 after Raymond James cut it to Market Perform from Outperform, trimming its 2027 EPS estimate by 1.1% on slower loan growth, tighter margin and higher provisioning. Q3 adjusted EPS was $0.63 against $0.67, with a single $37.6m commercial relationship moved to non-accrual, a $10m partial charge-off and a $17.8m reserve pushing provision expense to $9.6m from $2.2m. Piper Sandler had already cut to Neutral with a $30 target earlier in October.

The names that went up

Symbotic rose 3.2% pre-open after Walmart signed an Enterprise Master Automation Agreement committing an initial $6bn to deploy its robotics across 25 US regional distribution centres plus select markets in the Americas, with a further $125m for next-generation racking R&D. The deal could add roughly $6.92bn to a backlog already at $22.5bn; Q4 and full-year results come November 23. Rocket Companies gained 3.1% on Q3 adjusted EPS of $0.15 against $0.14 and GAAP revenue of $3.28bn versus $2.59bn expected, with adjusted EBITDA of $748m and a 29% margin, the best in nearly five years. CEO Varun Krishna cited share gains in purchase and refinance with mortgage rates at a three-year high. Compass Point kept Buy but cut its target to $15 from $18 on soft Q4 guidance of $2.10bn to $2.30bn against $2.57bn. ExxonMobil rose 1.8% to $186.62 on adjusted EPS of $4.23 and adjusted earnings of $17.5bn, net profit more than doubling to $15.4bn. Energy Products earnings hit a record $9.05bn, up 120% sequentially, with the article attributing roughly $4.5bn of the quarter to refining margins blown out by conflict damage to Saudi and Russian refineries and the partial closure of the Strait of Hormuz. The dividend went up 3.9% to $1.07 and $20bn of 2027 buybacks were reaffirmed; Chevron beat on the same refining tailwind.

Smaller full-text items

Three short pieces round out the read-in-full set. Arbor reported Q3 EPS of -$0.04 against a $0.04 estimate, with revenue of $56.42m versus $112.99m consensus; the stock closed at $3.02 and is down 70% over twelve months. ChoiceOne Financial Services beat with EPS of $0.97 against $0.93 and revenue of $45.19m versus $44.48m. MSA Safety declared a fourth-quarter dividend of $0.54 per common share, payable December 10 to holders of record November 13, plus $0.5625 on preferred.

The rest of the feed

The remaining roughly 180 items are headline-only and mostly low-signal: a long run of Form 8-K filing notices, short "shares may move X% on earnings" previews for European names like Daimler Truck, IAG, Amadeus and Aperam, and a large volume of TradingView chart posts on gold, bitcoin, Nvidia and the indices. A few headline items are worth noting as stated: Wedbush upgraded DoorDash on the Instacart deal, Susquehanna raised its eBay target to $125, Canaccord downgraded Stryker on weak execution and a market slowdown, Viatris launched a tender offer for Pacira at $36.50 a share, Hilton Grand Vacations announced a $200m accelerated buyback, MDA Space won a contract worth over $100m for EU satellite antennas, and Canada's August GDP was flat with StatCan flagging a likely 0.1% September decline. Beyond that, nothing in the headline-only portion carries detail I can stand behind.

What this feed mostly is

Two hundred items, and the bulk of it is third-quarter earnings wire copy plus a long tail of Form 8-K and Form 144 filing notices. Nineteen were read in full, and of those, four were filing stubs with no content beyond the fact that a document was filed (Hercules Capital, CubeSmart, Weyerhaeuser 8-Ks, and a Form 144 for Penguin Solutions). The genuinely substantive reading is a block of Investing.com quarterly results summaries, which I've grouped below.

Big-tech earnings backdrop, headline only

The index and mega-cap story running through the feed is headline-level only: U.S. stocks closed lower with the Dow down 0.25%, and separate headlines say Amazon slid over 6% after hours on a quarterly results miss, Intel tanked on weak Q4 guidance after mixed Q3 results, and an IBD wrap frames Amazon and Intel as the earnings losers after Google, ServiceNow and Fortinet hit the Nasdaq. Reddit gets three or four separate items saying shares slid and that the company will test a log-in requirement as search referral traffic slows, with the CEO quoted on search referrals dropping by more than a million per week in October. Starbucks beat on sales and profit yet is noted trading lower after hours; Roblox fell on user growth and guidance; Pinterest fell on a revenue miss; Twilio beat but fell on slowing organic growth; Coinbase posted a quarterly profit on lower expenses; Rivian beat and raised guidance on R2; Dexcom beat with revenue up 11%; Strategy posted record profit on bitcoin gains but fell on a revenue miss. I've only got the headlines on all of those.

FMC collapse is the single worst number in the feed

FMC reported Q3 EPS of minus $4.41 against a $0.07 estimate, a $4.48 miss, on revenue of $105.6 million versus consensus of $604.67 million. Guidance went with it: full-year 2026 EPS of minus $3.66 to minus $3.50 against a consensus of positive $1.20, and full-year revenue of $2.75 to $2.85 billion versus $3.26 billion expected. Q4 is guided to $0.56-$0.70 EPS against $0.94 consensus. The stock closed at $4.75, down 55.65% over three months and 69.41% over twelve, with seven negative EPS revisions and none positive in the prior 90 days. The article gives no explanation for the revenue shortfall or the loss.

Other full-text misses

PTC Therapeutics missed by $0.92, posting minus $0.62 against a $0.30 estimate, though revenue of $357.8 million beat the $304.05 million consensus and full-year revenue guidance of $1.29-$1.32 billion was raised above the $1.25 billion consensus. Pebblebrook Hotel also had the loss-with-revenue-beat shape: minus $0.56 versus a penny expected, on $402.74 million against $387.28 million, with the stock up 103% over twelve months. OFS Capital reported minus $0.86 against $0.07 on revenue of $5.94 million versus $6.59 million. PennyMac Financial earned $1.05 against $1.26 on revenue of $548 million that topped the $530.82 million consensus, with six negative EPS revisions in the prior 90 days and the shares down 48.6% over a year. None of these articles offer a cause.

Narrow industrial and utility misses

MasTec missed by a penny at $2.96 on revenue of $5.15 billion against $4.94 billion expected, and guided full-year EPS to $8.92-$9.30 versus $9.27 consensus on revenue of $18.30 billion against $18.19 billion; the shares are down 32.41% over three months. Edison came in at $1.92 against $1.98 on revenue of $4.89 billion versus $5.34 billion, with full-year EPS guidance of $5.90-$6.20 straddling the $6.12 consensus. Eastman Chemical missed by $0.10 at $1.84 on $2.39 billion against $2.41 billion. Olin missed by $0.02 at $0.13 on $1.75 billion against $1.83 billion. NPK International missed by $0.03 at $0.09 and cut full-year revenue to $300-$305 million against a $319.7 million consensus. Financial Institutions missed by $0.06 at $0.99 on $64.75 million versus $66.55 million.

Beats with soft revenue

A cluster of names beat on EPS while revenue came in light, which was the dominant pattern in the full-text batch. Mondelez earned $0.78 against $0.71 on revenue of $9.97 billion versus $9.98 billion, notable mainly because it had seen 14 negative EPS revisions against one positive over the prior 90 days. Erie Indemnity beat by $0.07 at $3.48 on $1.07 billion against $1.09 billion. Cousins Properties beat by a penny at $0.10 on $259.42 million versus $264.4 million. Bright Horizons beat by $0.04 at $1.80 but guided full-year EPS to $4.98-$5.03 against $5.11 consensus and revenue to $3.07 billion against $3.10 billion, and the stock is down 27.42% over twelve months.

Analyst notes and corporate actions, headline only

The analyst cluster runs both directions: Freedom Broker raised its ServiceNow target on AI growth, upgraded California Water Service on valuation, and cut Boeing on production concerns; Jefferies reiterated Buy on AMD citing data center upside and cut Baxter on valuation; Stifel cut Insmed to $195 on the opex outlook; Raymond James lowered First Financial Bancorp on the EPS outlook. On capital returns and corporate housekeeping, Voya raised its dividend 21% to $0.57, Delek US raised 18% to $0.30, Mohawk launched a $500 million buyback, Glacier Bancorp a $200 million one, Upbound announced a $50 million repurchase intent, and Cohen & Steers, Esquire Financial, Smithfield and Bristow declared dividends. Hormel named John F. Ghingo president and CEO, Monolithic Power named Tony Balow CFO, Cullen/Frost is moving its listing to the Texas Stock Exchange, CubeSmart took a $300 million unsecured term loan to 2031, Walmart committed $6 billion to expand its Symbotic deal, and Merit Medical bought Solo Pace for $45 million.

Commodities, geopolitics and crypto chatter

Headline-only across the board: crude fell on VP Vance outreach to Iran, natural gas fell on an EIA inventory build and warm weather, cocoa stayed weak on rising ICE inventories and possible Brazilian sales, coffee hit a one-month low on Brazilian sales concerns, while sugar rose on reduced Brazilian cane crushing. A DeItaone post reports Kyiv under Russian ballistic missile attack, and another reports $2.77 billion of outflows across five blockchains from Binance wallets amid drain suspicions with no hack confirmed. The remaining TradingView items are retail chart posts on gold, EUR/USD, GBP/USD, bitcoin, XRP and others, with nothing behind them but the headline.

Eli Lilly's blowout quarter

The biggest single story in the feed is Eli Lilly. Q3 2026 adjusted EPS came in at $7.48 against consensus of roughly $5.60 to $6.26, on revenue of $24.4 billion, up 39% year over year and about $1.8 billion ahead of estimates. Management raised full-year 2026 revenue guidance to $91-92 billion from $85-87 billion, versus a Street figure near $88.7 billion. Mounjaro did $10.72 billion and Zepbound $5.35 billion, both above estimates, with the new oral weight-loss pill Foundayo adding $184 million. CEO David Ricks put it down to broad global demand for the two tirzepatide drugs plus a doubling in newer oncology, immunology and neuroscience products. The night before, Lilly released Phase 3 TRANSCEND-T2D-2 data showing retatrutide delivered more than double the weight loss of Novo Nordisk's highest approved Ozempic dose in type 2 diabetics, which had already lifted the shares after hours. The stock was up 4.5% pre-open at $1,346.50, above its prior 52-week high of $1,321.21, against a soft tape. Barclays recently went to a $1,400 target; RBC and Morgan Stanley hold Overweight-equivalent ratings. A separate Investor's Business Daily headline covers the same beat-and-raise.

Carrier beat but sold off hard

Carrier Global is the mirror image. Adjusted EPS of $0.87 on $6.26 billion of revenue beat forecasts of $0.77 and $6.10 billion, organic sales grew 15%, adjusted operating profit about 35%, and margin expanded 260 basis points. Data center orders rose 300% in the quarter, with year-to-date data center orders above $3 billion and segment sales over $550 million. Even so the stock was indicated down 7.89% premarket at $51.83, near its 52-week low of $50.24. The reason given: Carrier raised its full-year sales outlook to nearly $24 billion but left adjusted EPS guidance unchanged at $2.85-2.90, cut the CSA segment margin outlook to roughly 19%, and flagged residential pricing realization coming in below plan. Year-to-date input cost headwinds run about $800 million, slightly under half tariff-related, with $550-600 million of that unexpected. CEO David Gitlin conceded the company was "chasing pricing a little bit" this year and has announced increases up to 10% across CSA, including 8% on residential late in Q4. A companion slides item covers the same quarter.

Textron and West Pharmaceutical raised guidance

Two clear beat-and-raise industrials. Textron earned $1.76 adjusted on $3.8 billion against $1.43 and $3.77 billion expected, lifted full-year EPS guidance to $6.55-6.65 and manufacturing cash flow to $800-900 million, mostly on roughly $100 million less capex. Aviation revenue rose 14% to $1.7 billion with the highest order bookings in nearly three years, Systems rose 16%, but Bell fell 9% to $933 million and the MV-75 low-rate production award has slipped into 2027, widening the expected charge range to $110-150 million from $60-110 million. Shares were up 4.72% at $82.02 premarket. West Pharmaceutical posted $2.66 adjusted EPS on $874.5 million, versus $2.20 and $827.1 million, with gross margin up 310 basis points to 39.7%. HVP Components grew 20% organically to $467 million on GLP-1 and biologics demand plus containment-rule upgrade projects, and Asia Pacific revenue rose 42%. Full-year guidance went to $3.41-3.42 billion of revenue and $9.38-9.48 EPS. The stock was up 4.8% at $423 premarket, just above its prior 52-week high.

Smaller beats with mixed reactions

Garrett Motion beat on profit, $0.51 against $0.47, and missed slightly on revenue at $930 million versus $940.71 million. Adjusted EBIT margin rose 160 basis points to 16.3%, free cash flow was $136 million, and commercial vehicle and industrial sales grew 23% organically. It lifted its 2027 industrial sales outlook to roughly $300 million, mostly genset power generation, and approved a new $250 million buyback. Shares were up 4.69% at $23.377. Silgan earned $1.31 against $1.25 but revenue of $2.04 billion missed the $2.10 billion estimate; it raised full-year EPS guidance to $3.83-3.93 and reaffirmed about $450 million of free cash flow, helped by fragrance and beauty, prescription pharma dispensing and wet pet food, with soup demand weaker than expected. Stock up 4.35% at $39.58. Proto Labs beat on both lines, $0.63 on $154.3 million of record revenue, and raised full-year growth guidance to 10-11%, but fell 3.2% premarket to $88 as gross margin slipped 140 basis points to 44.5% on raw material costs and machine upgrades, and Q4 EPS guidance of $0.46-0.54 sits below Q3. AXIS Capital missed on EPS at $2.75 versus $2.85 despite revenue of $1.79 billion beating $1.69 billion; the combined ratio widened to 94.0% from 89.4% on $75 million of catastrophe and war losses against $44 million a year ago, and shares fell 4.54% to $97.

Filler 8-K items with no content

Six of the full-text reads turned out to be empty Form 8-K stubs from Investing.com, for Catalyst Bancorp, Sidus Space, 374Water, bioAffinity, InterDigital and Azitra. The pages contain no filing detail at all beyond the ticker and a tick in the article header, so there is nothing to report from them.

Headline-only earnings and macro

The bulk of the remaining 180-odd items are headlines. On earnings, Cognizant is reported down 10% premarket on a weak Q4 outlook, Fortinet is referenced after a 25% post-earnings selloff, ServiceNow fell after its print, Bristol Myers slipped on short Opdivo sales and a cut to earnings guidance, and Norwegian Cruise Line is described as soaring on a beat-and-raise. Alphabet gets two angles: a headline that shares tumbled 10% as a search slowdown overshadowed cloud strength, and a TradingView piece asking why the stock is selling off despite AI growth. Others reporting include Hippo (beat, raised guidance), Bunge, LKQ, Everest Group, Ranpak, Axalta, CRH, Cimpress, T. Rowe Price, Republic Airways, Coastal Financial, Pitney Bowes, NovoCure, Cogeco and a batch of Indian names. On macro, US initial jobless claims came in at 194K, described as beating expectations and near 57-year lows, and Q3 GDP growth is reported as accelerating and above forecasts. A widely-quoted post has the euro falling 0.4% to $1.11095, its lowest since May 2025.

Analyst notes and corporate actions

There is a visible Stephens cluster: target raises on Regional Management, Prosperity Bancshares, First Interstate BancSystem and Kirby, a cut on PROG Holdings over leasing concerns, and a C.H. Robinson target lowered to $190 on claims costs. Elsewhere Needham raised Q2 Holdings to $85, Argus upgraded Biogen on rare disease strength, Truist reiterated Buy on Clean Harbors with a $365 target, and Deutsche Bank initiated positively on TK Accelis. On deals and capital, Thrive Holdings is reported acquiring ADT for $7.6 billion in cash, Ambev approved a buyback of up to 190 million common shares, FTAI Aviation announced a $500 million accelerated repurchase, Freedom Holding's subsidiary entered a $1.16 billion bond investment agreement, BioMarin licensed a Fabry disease therapy for $70 million upfront, Eightco sold its OpenAI stake at a 40% gain, and Kalshi is reported at a $40 billion valuation after a $1 billion round co-led by Wellington and Sequoia. UBS reported 3Q26 net profit of 2.7 billion.

Geopolitics, commodities and chart posts

A sizeable tail of the feed is technical-analysis posts on TradingView covering gold, bitcoin, EURUSD, USDJPY, the Nikkei, Hang Seng, DAX and various crypto pairs, none of which carry reported news. On the geopolitical side, headlines reference an Iran war adding $11 billion a month to the EU's oil import bill, Air France suspending Riyadh flights to December 12 and Dubai flights to November 7, and a Kremlin aide warning that Ukrainian attacks during November 4 celebrations could affect Russia's stance on trilateral talks. Javier Blas notes US retail gasoline prices are down more than 5% over the past month even as oil has risen. One further item says Nvidia CEO Jensen Huang has been caught up in a reported Chinese spy probe as AI stocks slide.

Microsoft's Azure quarter

The biggest piece of real substance in the feed is Microsoft's fiscal Q1 2027, covered in full. Revenue came in at $92.3 billion, up 19% year over year against consensus near $90.7 billion, and adjusted EPS of $4.89 beat the $4.72 expected. Azure was the standout: up 48% to $33.2 billion, ahead of the company's own 44%–45% guidance and up from $29.4 billion the prior quarter. Commercial backlog reached $677 billion, up 73%. The article notes Microsoft stayed cash-flow positive even with capex roughly doubling, which speaks directly to the AI-spending-discipline worry that had been hanging over Big Tech since Meta's results. The stock rose 4.5% after hours to $554.68, above its prior 52-week high of $551.15. The Nasdaq had closed the regular session down 0.6% ahead of the Fed decision on October 29, with rates widely expected to hold at 3.75%–4.00%.

Alphabet misses on earnings, cloud booms

Alphabet is the mirror image and it's covered from several angles here. The earnings item reports Q3 EPS of $2.12 against a $3.02 estimate, a $0.90 miss, on revenue of $127.6 billion versus $127.22 billion expected. Headlines around it say shares fell 7% after hours despite the cloud number, with separate posts breaking out Google Cloud revenue up 102.6% to $30.7 billion and operating income up 209.4% to $11.1 billion, Search up 12% to $63.4 billion, YouTube ads up 9.2%, and Alphabet raising roughly $41.1 billion in the quarter through $28.7 billion of senior unsecured notes and $12.4 billion of at-the-market equity. Another headline flags heavier-than-expected cash burn from cloud spending. So the two megacaps reporting the same evening were judged on the same question, AI capex versus returns, and landed on opposite sides.

Bausch Health earnings and balance sheet

Bausch Health rose 11.5% after hours on Q3 2026 results. Adjusted EPS was $1.77 against consensus near $1.27, revenue $2.94 billion against $2.72–$2.75 billion expected and up roughly 10% year on year. Management raised full-year revenue guidance to $10.975–$11.175 billion and lifted the adjusted EBITDA outlook. The board also authorised a $50 million buyback starting early November, aimed at offsetting dilution from employee equity, and the company said it will fully redeem about $643 million of 8.500% senior notes due 2027 from cash on hand, with a November 30 redemption date. The article is explicit that the broader tape gave no help, with the S&P 500 off 0.3% and the Nasdaq down 1.0%, so the move was all company news.

Other reported results read in full

Carvana posted Q3 EPS of $0.39, five cents below the $0.44 estimate, on revenue of $8.04 billion versus $7.67 billion expected; the stock had closed at $59.06, down about 5% over three months and 16.6% over twelve. A separate headline quotes the CEO citing retail units up 39% to a record 217,385 and net income up 83.7% to $483 million, with shares up 8% after hours. Mechanics Bancorp missed by eight cents at $0.20 EPS but beat on revenue, $225.72 million against $199.63 million. Happen beat by five cents at $0.50 while revenue of $263.16 million fell short of the $273.48 million expected; it guided Q4 EPS to $0.43–$0.48 against $0.46 consensus and FY26 to $1.87–$1.92 against $1.85.

Earnings headlines beyond the full reads

A long list of results sits here as headlines only, with no detail beyond what each line states. Beats: Ford (by $0.08, revenue topped, with other headlines saying it raised guidance and shares edged lower), T-Mobile (by $0.33, plus a raised annual free cash flow forecast), Gen Digital, Align, MYR Group (by $0.83), Sterling Infrastructure (by $1.38), Everspin, Origin Bancorp, Regional Management, Alerus Financial, McGrath, Cohu (on AI demand), Flowserve, and Glaukos, said to be up 13% on the beat and raised guidance. Misses and weak reactions: Everest by $0.53 with revenue short, ServiceNow down 16% after hours, Fortinet with revenue growth described as underwhelming, Align down 5% on a weak Q4 revenue outlook despite the beat, and Sprouts Farmers Market down 15% on guidance and a Q3 miss. Also here: eBay up on Q3, Chipotle beating on sales, FedEx raising its outlook, Honeywell Aerospace lifting its second-half free cash forecast, Stellantis reporting €37.6 billion of net revenues, and Infosys at $5,145 million with $5.2 billion of large deal TCV.

Fed, macro and geopolitics

Headlines carry the Fed holding rates steady as expected with two policymakers preferring a 25bp hike, and Wall Street ending slightly higher after it. Bessent soundbites cover an energy supply shock and a wish for the Fed to keep an open mind, confidence in Warsh, and an expectation of a strong Q3 GDP print. Separately, Vance has reportedly written to Iran's top security official to restart talks ahead of possible US strikes after the midterms, per the WSJ lines in the feed. Commodity headlines: cocoa lower on rising ICE inventories and possible Brazilian sales, sugar higher on reduced Brazilian milling, coffee at a two-week low on a weaker real and arriving beans, nat gas up on cooler forecasts and restored LNG shipments.

Corporate actions and analyst notes

Smaller items with real content: Markel entered a $2.3 billion reinsurance deal with Enstar, Amrize completed a $1 billion buyback, Radian named Daniel Kobell CFO, Q2 Holdings appointed Jonathan Price co-CEO and reported Q3 revenue of $225.8 million with raised guidance, Rio Tinto is adding lithium plants in Argentina, and SPACCircle Acquisition closed a $100 million Nasdaq IPO. Analyst moves, all headline-only: Oppenheimer raised its Masco target on earnings growth, Stifel took GE HealthCare to $90 on a strong Q3, Mizuho raised AxoGen to $65, Jefferies raised Etsy to $100, and Freedom Broker upgraded Royal Caribbean on Q3 results. Routine dividends from PVH, IFF, Black Hills and Hennessy Advisors.

The rest is filing noise

A large share of the 200 items is boilerplate. Ten of the twenty full reads were Form 8-K stub pages from Investing.com for Axis Capital, Q2 Holdings, SEACOR Marine, KLA, Universal Display, Pitney Bowes, CONMED, Houlihan Lokey, Morningstar, Impinj, UFP Industries and ABM, and they contain nothing beyond the ticker and the filing date. Add to that a run of Nasdaq screener outputs on oversold ETFs and moving-average crosses, a batch of TradingView chart posts on bitcoin, ETH, gold and FX pairs, and assorted insider Form 4s. Nothing in that group carries information worth your time.

AxoGen jumps on beat and raised guidance

The biggest mover in the full-read items is AxoGen, up 20.53% in premarket trading to $45.15 from $37.46. Third-quarter adjusted EPS came in at $0.21 against a $0.13 estimate, with revenue of $75.8 million versus $73.16 million expected, up 26.2% from a year earlier. Breast reconstruction was the fastest-growing piece, with revenue in that segment up more than 60%, and Avance Nerve Graft made up 64% of revenue. Management raised full-year guidance to at least $290 million, or growth of at least 29%, with $283 million organic. The recently acquired BioCircuit brings NerveTape and should add at least $7 million in the fourth quarter and roughly $34 million in 2027 net of cannibalisation. Commercial payer coverage for Avance now reaches about 96% of US covered lives. Gross margin was 74.8%, down 180 basis points year on year on higher product costs but up sequentially from 72.7%.

Evercore's record quarter

Evercore rose 9.55% premarket to $284.68. Adjusted EPS of $4.28 beat the $2.53 estimate by 69%, and revenue of $1.17 billion came in 33% above the $878 million forecast. Adjusted net revenues were up 13% year on year at roughly $1.2 billion, a sixth consecutive quarterly record, with advisory fees of $1 billion. The compensation ratio fell to 63% from 65%, and the firm returned $189 million in the quarter, over $1 billion year to date. CEO John Weinberg pointed to record backlogs replenishing at a healthy rate; management also said non-M&A businesses now account for more than 40% of firmwide adjusted net revenues over the last four quarters. Note the stock had fallen 23% over the prior six months.

Beat-but-sold cluster: Blackbaud, V.F., Chefs' Warehouse

Three companies beat and still fell premarket, which is the clearest pattern in today's full reads. Blackbaud dropped 8.75% to $49 despite non-GAAP EPS of $1.36 against $1.33, because revenue of $292.64 million was essentially dead on the estimate; growth was 4.1%, free cash flow was $126 million, and the 2026 renewal cohort is about 40% larger than 2025's, which management said is weighing on reported growth into early 2027. V.F. Corp fell 3.82% to $16.38 after EPS of $0.70 against $0.53 and revenue of $2.7 billion against $2.66 billion, with gross margin up 290bp to 55.4%; Vans still fell 9.8% in the quarter and the company flagged $70 million to $80 million of unmitigated tariff costs in the second half. The Chefs' Warehouse fell 3.66% to $105 after EPS of $0.66 versus $0.58 and sales up 11.2% to $1.135 billion, with adjusted EBITDA up 26.3% and full-year guidance raised to $4.56–$4.61 billion in sales; the article notes the stock is up 86% over the past year on a P/E above 51.

GE Vernova orders and the Trench deal

GE Vernova beat on both lines, EPS $4.81 against $4.00 and revenue $12.64 billion against $12 billion, but shares rose only 0.55% premarket to $900. Orders nearly doubled, up 96% to $29.3 billion with book-to-bill above 2.0x, and backlog grew from $176 billion to about $200 billion. Free cash flow was $5.4 billion, up $4.7 billion year on year. Full-year guidance went up to $46.5–$47.5 billion revenue, 13.5–14.5% adjusted EBITDA margin and $16–$17 billion free cash flow, with Power margins hitting 21.4%. The company announced the Trench Group acquisition for its high-voltage grid business and doubled its buyback to $20 billion. Wind remains the soft spot. A separate headline-only slide deck item puts the Trench price at $9 billion.

European and Indian names

KPIT Technologies rose 3.87% to 552.5 on a quarter management called in line: revenue up 6.5% in rupee terms but roughly flat in constant currency, EBITDA margin up 60bp to 17.8%, product revenue up 25%, off-highway and commercial vehicles up 27%, passenger cars down 7%. Two large customers cutting or cancelling programmes cost the equivalent of 13% of sales, and margins are not expected back to 20–21% until early FY2028. KPN gained 2.87% to $4.199 on revenue of $1.5 billion against $1.47 billion expected, with group service revenue up 2.7% and EPS exactly in line; it reaffirmed its dividend and the EUR 250 million buyback. Epiroc went the other way, down 2.6% to $209.8 even with orders up 12% organically to SEK 17.5 billion and adjusted margin up to 20.4%, as operating cash flow fell to SEK 1.4 billion from SEK 2.5 billion on inventory build and long equipment lead times delay revenue conversion.

Smaller financials

OceanFirst posted core EPS of $0.48 against $0.40 and revenue of $185.13 million against $177.79 million in its first full quarter with Flushing Financial; net interest income rose to $172 million and core expenses of $114 million came in under the $120–125 million guide, though GAAP EPS was just $0.17 after $0.30 of merger costs. The stock barely moved. John Marshall Bancorp earned $0.55 against a $0.50 estimate on revenue of $18.06 million versus $18.61 million expected. HBT Financial declared a quarterly dividend of $0.25, payable 17 November to holders of record 9 November; the article notes the stock is up 55% over the past year near its 52-week high, and recent target raises from Keefe Bruyette & Woods to $43 and DA Davidson to $38.

What the headline-only items flag

A lot of this feed is routine Form 8K filings with no content behind them, plus a wall of TradingView chart posts. The headlines worth knowing about, without more detail than the headline gives: Boston Scientific fell 11% with a cybersecurity attack cited as weighing on guidance, Dropbox is cutting about 9% of its workforce with its CTO departing, LCI Industries confirmed an unsolicited non-binding $101-per-share cash proposal from Monomoy Capital Partners, and Artiva halted a cell therapy after patient deaths and cut 94% of staff. Robinhood fell on a Q3 miss with analyst target cuts, GSK dropped on weaker vaccine sales, and Sandoz cut its sales outlook. On earnings still to land, Alphabet and Microsoft report and the Fed decision is due. In the UK, Healey delivered his first budget, cutting the 2027 growth forecast to 1% and fiscal headroom to about £15 billion. Elsewhere: SK Hynix shares surged on a profit beat, Stellantis beat on revenue, EQT is acquiring Range, IREN secured $363 million of equipment financing, Scripps raised its political ad outlook while cutting 850 jobs, and the US goods trade deficit widened unexpectedly to $134.9 billion.